Europe Ovarian Cancer Diagnostics and Therapeutics Market - Segmented by Type of Cancer and Geography 2017 - 2022

  • ID: 4388330
  • Report
  • Region: Europe
  • 121 pages
  • Mordor Intelligence
1 of 4
The European market for ovarian cancer diagnostics and therapeutics accounted for USD 359 million in 2015 and is expected to grow at a CAGR of 10-16% by 2020.

Ovarian cancer is caused by an uncontrollable cell growth in the ovarian tissue. It is a growing concern as it is one of the most common causes of death in women across the globe. Thereby, the need to develop new medication and therapies for the effective treatment of this disease, and new methods for the timely diagnosis of ovarian cancer, is increasing. Thus, the market for ovarian cancer diagnostics and therapeutics is at a stage of huge development. Europe is the second largest market for ovarian cancer diagnostics and therapeutics.

Europe Ovarian Cancer Diagnostics and Therapeutics Market-Market Dynamics

The report details several factors driving and restraining the market, some of which are listed below.

Drivers

Increasing incidences of ovarian cancer worldwide

Increasing population of aged women

Greater use of combination therapies for the treatment

Increase in healthcare expenditure

Increased government funding

Increasing healthcare awareness

Restraints

Launch of generic drugs

Patent expiry of key drugs

Lack of accurate diagnosis of ovarian cancer

The market for ovarian cancer diagnostics and therapeutics is segmented on the basis of type into epithelial ovarian tumors, ovarian germ cell tumors, ovarian stromal tumors and primary peritoneal carcinoma. Based on the cancer stage, the market is segmented into Stage I, Stage II, Stage III, and Stage IV. Based on the diagnosis, the market is segmented into physical examination, biopsy, blood tests, Human Chorionic Gonadotropin (hCG) test, ultrasound, MRI, PET, and CT scans. Based on the treatment, the market has been segmented into chemotherapy, targeted therapy, radiation therapy, immunotherapy, hormonal therapy, and surgery. Based on geography, the market is segmented into the UK, France, Germany, Scandinavia, Italy and Rest of Europe.

Major Companies in the Sector Include:

This Report Offers:

Market definition along with identification of key drivers and restraints for the market.

Market analysis with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. Introduction
1.1 Report Description
1.2 Research Methodology
2. Executive Summary
3. Market Overview
3.1 Market Definition
3.2 Market Drivers
3.2.1 Increasing Incidences of Ovarian Cancer
3.2.2 Aging Population of Women
3.2.3 Greater Use of Combination Therapies for the Treatment of Ovarian Cancer
3.2.4 Increase in Healthcare Expenditure
3.2.5 Increased Government Funding
3.2.6 Increasing Healthcare Awareness
3.3 Market Restraints
3.3.1 The Launch of Generic Drugs
3.3.2 Patent Expiry of Key Drugs
3.3.3 Lack of Accurate Diagnosis of Ovarian Cancer
3.4 Market Opportunities
3.5 Market Threats
4. Porter’s Five Force Analysis
4.1 Bargaining Power of Suppliers
4.2 Bargaining Power of Buyers
4.3 Degree of Competition
4.4 Threat of Substitution
4.5 Threat of New Entrants
5. Market Segmentation
5.1 By Cancer Type
5.1.1 Epithelial Ovarian Tumors
5.1.2 Ovarian Germ Cell Tumors
5.1.3 Ovarian Stromal Tumors
5.1.4 Primary Peritoneal Carcinoma
5.2 By Cancer stage
5.2.1 Stage I
5.2.1.1 Stage IA
5.2.1.2 Stage IB
5.2.1.3 Stage IC
5.2.2 Stage II
5.2.2.1 Stage IIA
5.2.2.2 Stage IIB
5.2.2.3 Stage IIC
5.2.3 Stage III
5.2.3.1 Stage IIIA
5.2.3.2 Stage IIIB
5.2.3.3 Stage IIIC
5.2.4 Stage IV
5.3 Diagnosis
5.3.1 Physical Examination
5.3.2 Biopsy
5.3.3 Blood Tests
5.3.4 Human Chorionic Gonadotropin (hCG) Test
5.3.5 Ultrasound
5.3.6 MRI
5.3.7 PET
5.3.8 CT Scan
5.4 Treatment
5.4.1 Chemotherapy
5.4.1.1 Localized Ovarian Cancer Therapeutics
5.4.1.2 Metastatic Ovarian Cancer Therapeutics
5.4.1..3 Recurrent Ovarian Cancer Therapeutics
5.4.2 Targeted Therapy
5.4.3 Radiation Therapy
5.4.4 Immunotherapy
5.4.5 Hormonal Therapy
5.4.6 Surgery
5.5 By Geography
5.5.1 Europe
5.5.1.1 UK
5.5.1.2 Germany
5.5.1.3 Scandinavian Regions
5.5.1.4 Italy
5.5.1.5 France
5.5.1.6 Rest of Europe
6. Competitive Landscape
7. Company Profiles
7.1 Bristol Myers Squibb Company
7.2 Eli Lilly and Company
7.3 GlaxoSmithKline PLC
7.4 Janssen Pharmaceuticals, Inc.
7.5 Novogen, Inc.
7.6 Genentech Inc.
7.7 Astra Zeneca
7.8 Boehringer Ingelheim GmbH
7.9 F. Hoffman-La Roche Ltd
8. Appendix
8.1 Abbreviations
8.3 Bibliography
8.4 Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll